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Key messages 
1. Use the concept of ‘positive health’ for non-specific low back pain - the ability to 
adapt and to self-manage, in the face of social, physical and emotional challenges. 
2. Avoid harmful and useless treatments by adopting a similar framework to drug 
regulation - only include them in public reimbursement packages if proven safe, 
effective and cost-effective. 
3. Address widespread population and health professional misconceptions about the 
causes and prognosis of low back pain and the effectiveness of different treatments, 
and fragmented and outdated models of care. 
4. Policy, public health, health care practice, social services and workplaces must jointly 
tackle the ‘low back pain paradox’ in low- and middle-income countries where 
improving social and economic conditions could prevent or reduce low back pain 
incidence, but at the same time create expectations and demands for medical 
investigations and low-value health care that increase the risk of long-term backrelated 
disability. 
Word count: 2,220 words 
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Low back pain is the leading worldwide cause of years lost to disability and its burden is 
growing in tandem with the increasing and ageing population.1 As these population shifts 
are more rapid in low- and middle- income countries, where adequate resources to address 
the problem may not exist, the impacts will likely be more extreme in these regions. Most 
low back pain is unrelated to specific identifiable spinal pathology, and our Viewpoint, the 
third paper in this Lancet series,2,3 is a call for action on this global problem of non-specific 
low back pain. 
The challenges 
Panel 1 summarises the most pressing political, public health and health care challenges and 
identifies actions to meet them. Preventing the onset and persistence of disability 
associated with low back pain requires recognition that the disability is inseparable from the 
social and economic context of people’s lives and is entwined with personal and cultural 
beliefs about back pain.4 Health and workplace policies and disability payment systems are 
often ineffective and wasteful and represent key targets for improvements. 
Socioeconomically disadvantaged people are overrepresented among those with disabling 
low back pain.5 In many settings they will be further disadvantaged by restricted access to 
accurate information sources, health care approaches that provide appropriate support for 
self-management of uncomplicated low back pain, and to more specialised effective 
interventions, such as multidisciplinary rehabilitation, for more complex persistent low back 
pain. 
While independent associations are uncertain, public health programmes that tackle 
lifestyle issues of obesity and low levels of physical activity may provide a model and 
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structure for reducing the impact of low back pain on daily life.6 Implementation of these 
programmes are especially pressing in some low- and middle-income countries where 
increasing obesity rates and rapid industrial growth and consequent reductions in physical 
activity are occurring in urban areas. Health system and societal initiatives addressing low 
back pain should synergise with the WHO European Region Action plan for the prevention 
and control of non-communicable diseases which recognises the need for comprehensive 
promotion of musculoskeletal health. As low back pain disability affects employability in 
many informal sectors, multi-sectorial integration between health, labour and social 
services should also be a key goal. 
Disabling low back pain is partly iatrogenic. Studies in low-income countries and indigenous 
and acculturated populations in high-income countries report harmful consequences from 
exposure to health care per se.7-9 Such negative effects reflect changes from traditional 
views (low back pain is a relatively benign part of daily life), to low back pain being a 
problem requiring medical attention. Increased use of ineffective and potentially harmful 
treatments has wasted limited health care resources and caused harm. The current 
epidemic of addiction and rising mortality resulting from increased opioid prescribing in the 
U.S. over the past 20 years provides a dramatic example of the disastrous effects of harmful 
medical intervention.10 In low- and middle-income countries, epidemiological evidence 
suggests that improving social and economic conditions could prevent or reduce low back 
pain incidence, but at the same time create expectations and demands for medical 
investigations and low-value health care that paradoxically increase the risk of long-term 
back-related disability (the ‘low back pain paradox’). 
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The global challenge is to prevent the introduction and use of practices that are harmful or 
wasteful while at the same time ensuring equitable access to effective and affordable health 
care for those who need it. High rates of advice to rest and use of ineffective treatment 
modalities are already a reality in low- and middle-income countries. While overmedicalisation 
disproportionately affects the wealthy minority, it also threatens to reduce 
or obscure availability of high-value health care services for the poorer majority and further 
widen health and social disparities. Contextual factors, such as lack of suitable available 
work duties, may also mean that what would be considered appropriate in high-income 
countries, such as encouragement to remain or return early to work for people with low 
back pain, may not always be appropriate (or even an option) in less affluent countries. 
Protection of the public from unproven or harmful approaches to managing low back pain 
requires that governments and health care leaders tackle entrenched and 
counterproductive reimbursement strategies, vested interests and financial and 
professional incentives that maintain the status quo. Funders should only pay for high-value 
care, stop paying for ineffective or harmful tests and treatments, and commission research 
on those that are unproven. Similar to strict drug regulations in many countries, new tests 
and non-drug treatments should only be available in trials until their status is established. 
Some countries are testing these approaches. In Australia, a clinician-led taskforce is 
reviewing all government-subsidised tests and procedures with the aim of removing funding 
for those that are unnecessary, outdated or potentially unsafe. In the Netherlands, 
unproven interventions are conditionally included in the public health insurance package 
only if there is an evaluation to inform a final decision. Stakeholders, including patients, 
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agree in advance to design and eligibility criteria for the evaluation. This framework has 
already assessed radiofrequency denervation for patients with chronic low back pain.11 
As this treatment was not found to provide significant added benefit over a standardised 
exercise program alone, it is no longer being reimbursed. 
A new approach to low back pain 
The biopsychosocial model of low back pain has brought significant advances in 
understanding the prognostic significance of psychosocial factors in individual patients. It 
has had less success shifting practitioners away from managing patients within a biomedical 
framework. The importance of behavioural approaches to back pain management does not 
obscure the continuing need to investigate mechanisms and potential biological 
determinants of non-specific low back pain in phenotypically distinct subgroups. 
However, to move the field forward we propose adoption of the ‘positive health’ concept as 
the overarching strategic approach to the prevention of long-term disability from low back 
pain.12 Positive health, as proposed by Huber et al, is ‘the ability to adapt and to selfmanage, 
in the face of social, physical and emotional challenges’. This term encompasses a 
much broader concept of health than simply ‘absence of disease’ and its emphasis on 
medicalisation and cure. 
There is evidence that population levels of long-term disabling low back pain could be 
reduced by adopting this positive health approach. 13,14 For health professionals, positive 
health focuses on alternatives to ‘treatment’ and ‘cure’ that promote high-quality, 
meaningful lives for people with persistent low back pain. Public and patient expectations 
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will need to change, with people not expecting a diagnosis or complete cure for their low 
back pain. This requires initiatives to change widespread and inaccurate beliefs about back 
pain,13 helping the next generation to avoid counterproductive patterns of illness behaviour. 
For people with persistent low back pain, positive health entails learning how to cope with a 
long-term health problem through self-management activities, seeking health care only 
when needed. While passive approaches such as rest and medication are linked with 
worsening disability, active strategies such as exercise are associated with lower levels of 
disability and less reliance on formal health care. There are numerous behavioural and 
cognitive strategies that people with chronic pain in the community use, regardless of 
whether or not they seek care.15 In the occupational setting, interventions focusing on 
positive health, including peer support for the notion that low back pain is not an ‘injury’ in 
need of medical treatment,16 and redirecting problem-solving efforts away from seeking 
cures towards improved adaptation to the pain, yield beneficial outcomes.17 
Improved training and support of primary care doctors and other professionals engaged in 
activity and lifestyle facilitation (e.g. physiotherapists, chiropractors, nurses, community 
workers) could minimise use of unnecessary medical care. System changes that integrate 
and support health professionals from diverse disciplines and care settings to provide 
patients with consistent messages about mechanisms, causes, prognosis and natural history 
of low back pain as well as the benefits of physical activity and exercise, are crucial to 
changing behavior and improving delivery of effective care. Traditional healers where 
integrated into the health care system, community health workers and family remain 
important providers of lower cost basic education and/or care in many low-income 
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countries for the majority of people with low back pain who do not require medical 
attention.18 In rural and remote regions ‘tele-rehabilitation’ blended with self-management 
may be an option where internet access is available. 
What should be known about low back pain? 
The success of a positive health approach will depend on whether relevant stakeholders 
share the same mission, vision and objectives and the success of strategies for knowledge 
transfer and exchange. Panels 2 and 3 list information that well-informed consumers, 
patients, clinicians and policy makers should know about low back pain and its global 
burden. 
Policy-makers in all countries should look to local stakeholders to help decide what is best 
and appropriate for their individual setting. As in other fields of development, low- and 
middle-income countries should ensure that investment in musculoskeletal services is 
effective for patients and does not harm local health systems.19 Local participation and 
ownership, integration with existing priorities and policies, and coordination with national 
and regional systems and processes are crucial. 
The research and evidence challenge 
Funding for low back pain research is limited and uncoordinated. This particularly affects 
low- and middle-income countries where the effects of disabling low back pain remain 
under-recognised and research priorities and funding remain focused on infectious diseases. 
One way forward would be a global network of low back pain researchers from developed 
and developing countries, pooling experience and knowledge and building research capacity 
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where it is needed. Reducing research waste is a priority, achievable by ensuring that 
research studies focus on the most important stakeholder questions, are large and rigorous 
enough to provide definitive answers, have the potential to significantly improve outcomes, 
and test interventions that can be quickly and widely implemented into practice. 
Panel 4 lists major research priorities. These align with priorities previously identified by the 
international low back pain primary care research community.20 Implementation research to 
determine how best to put existing knowledge and evidence to use through changes in 
patient and clinician behaviour and health system design is necessary in all countries. For 
low- and middle-income countries, priorities include identifying interventions that are 
optimal given the social, political, cultural and health resource context. While current 
evidence-based guidelines may be well suited for high-income countries and highly 
developed health care systems, they may need adaptation to assure feasibility and cultural 
appropriateness for low resource settings. 
Monitoring and surveillance 
An active ongoing monitoring and surveillance system is vital to evaluate the effects of new 
strategies on outcomes such as disability, ability to work and social participation. There is a 
pressing need for surveys and health care databases in different countries that use common 
metrics for measuring low back pain burden, use of active self-management strategies such 
as exercise, tests and treatments, and outcomes and costs of care. Panel 5 shows an 
indicator set for surveillance and monitoring. Uniform data collection would encourage 
benchmarking of health services within and across countries. Standardised low back pain 
definitions for prevalence studies have already been developed and incorporated into the 
Comment [RB1]: check 
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Global Alliance for Musculoskeletal Health Surveillance Taskforce survey module for 
musculoskeletal conditions. 
Conclusion 
Action is needed to address the growing burden of low back pain on many millions of 
people worldwide. Future social change, including ageing, urbanisation, sedentary lifestyles, 
and the development and promotion of new technologies, will likely exacerbate this 
problem. Examples of new technologies that may exacerbate the problem include the use 
and promotion of increasingly sensitive imaging techniques such as MRI that reveal 
‘abnormalities’ that may be incorrectly inferred to be the cause of a patient’s symptoms. 
Better recognition of the growing burden of low back pain is crucial to stimulate new, more 
effective strategies of prevention and care. The impact of disabling low back pain can be 
reduced through social change that supports full participation in daily life. In low- to middleincome 
countries, the ‘paradox of low back pain’ needs to be addressed. Other barriers to 
optimal evidence-based management range from widespread population and health 
professional misconceptions about the causes and prognosis of low back pain and the 
effectiveness of different treatments, fragmented and outdated models of care, and the 
widespread use of ineffective and harmful care, particularly in countries considered to be 
models of high quality care. 
We have described actions all countries can take to reduce the impact of disabling low back 
pain on their populations. Strong and coordinated political action from international and 
national policy makers, including the World Health Organisation and research funding 
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agencies is needed. Such action could significantly reduce disability and suffering and 
improve the effectiveness and efficiency of care for people with low back pain throughout 
the world. 
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Panel 1: Call for actions for meeting the political, public health, health care and research 
challenges to preventing disabling low back pain 
Actions to meet the political challenge of a lack of recognition of the impact and burden of 
back pain by international and 
national policy makers 
Call on the World Health Organisation to put disabling low back pain on the target list for all nations and 
increase attention on 
(i) the burden it causes (ii) the need to avoid excessively medical solutions and (iii) the need to integrate low 
back pain into all 
chronic disease initiatives 
Call on international and national political, medical and social policy leaders to adequately fund public health 
strategies 
focused on preventing low back pain from interfering with life, ensuring inclusion of disadvantaged and 
culturally diverse 
populations 
Call on national and international funding agencies to make low back pain research a global health priority in 
recognition of its 
impact on people’s lives in low-, middle-, and high-income countries 
Actions to meet the public health challenge of preventing the onset and persistence of the 
disability associated with low back 
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pain 
Change the priorities: 
o Prioritise low back pain, together with other musculoskeletal conditions, as a public health problem 
o Develop and implement positive strategies for primary prevention of disabling low back pain that are 
integrated with 
strategies for preventing other chronic conditions (physical activity, maintenance of healthy weight, mental 
health) 
o Develop and implement strategies to address modifiable risk factors for disabling low back pain at all levels 
(society, 
workplace, health professionals, individuals) 
Change systems and change practice 
o Integrate back pain care with public health initiatives providing credible advice that people who develop 
low back pain 
should stay active and remain working and people with low back pain should be supported in early return to 
work 
o Develop and implement strategies to ensure early identification and adequate education of low back pain 
patients at 
risk for persistence and disability 
o Promote a healthy lifestyle and address common comorbidities, in patients with persistent low back pain. 
Tackle social 
determinants of disability. Incentivise work through change and adaptation of the workplace and the job, and 
change 
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worker disability policies which do not improve/promote/support return to work 
o Consider provision of financial incentives to resume appropriate work without risk of loss of benefits for 
people who 
are off work due to low back pain 
o Promote active multidisciplinary rehabilitation to support return-to-work 
Actions to meet the health care challenge of continued emphasis on a biomedical and 
fragmented model of care 
Change culture 
o Develop interventions to address misconceptions about low back pain among health professionals, patients, 
the media 
and the general public 
o Promote ‘living well’ with low back pain: person-centred care focusing on self-management and healthy 
lifestyles as a 
means of restoring and maintaining function and optimising participation 
o Investigate the effectiveness and place of traditional practices for reducing low back pain disability in low- 
and middleincome 
countries 
Change clinician behaviour 
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o Invest in implementation research to address evidence-practice gaps across all relevant health care 
providers 
o Identify and implement effective behaviour change and training interventions to improve and integrate 
care 
o Deliver a workforce fit-for-purpose which includes targeted training of health care professionals and others 
with the 
right competencies and resolve to deliver evidence-based care 
o Build consensus across clinical disciplines, patient groups and journal editors for shared guidelines of care 
that are 
straightforward and non-denominational 
Change systems 
o Develop clear care pathways, referral, funding and information technology systems to enable people to see 
the right 
person for delivery of the right treatment at the right time, while precluding use of alternative inappropriate 
pathways 
o Develop consistent evidence-based clinical care standards and key indicators integrated across healthcare 
systems and 
settings 
o Develop and implement cost-effective strategies that provide access to effective care in low- and middle-
income 
countries for all 
Tackle vested interests 
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o Government, insurers and commissioners should consider tackling conflicts of interest through regulation 
and 
contracts, including not paying for inappropriate tests and for unnecessary, ineffective and harmful treatments 
o Existing and new tests and procedures for low back pain should be regulated in the same way as drugs; 
there should 
be evidence that they are safe, effective and cost-effective before they get reimbursed within public health 
care 
systems 
o Introduce incentives for effective and efficient care and disincentives for continued use of ineffective and 
potentially 
harmful approaches 
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Panel 2: What should well-informed consumers, patients and clinicians know about low 
back pain? 
Bed rest can delay recovery from back pain 
Early return to normal activity and work speeds recovery 
Pain does not always equal injury, especially long-term pain 
It isn’t necessary to be pain-free to have a healthy, productive life; usually it is best to 
continue or resume activity before the pain is gone 
For those who find it difficult to resume activity, there are people and programmes of 
care in health centres and workplaces to help 
Only a small number of people will have an identifiable cause for their back pain that 
calls for use of a specific treatment 
Many people should be encouraged to self-manage—and avoid unnecessary 
engagement with health care, including diagnosis and treatment 
Because the experience of pain has effects on both body and mind, treatments targeted 
at both have greater potential for reducing pain and disability than medical care alone 
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Panel 3: What should well-informed policy-makers know about low back pain? 
Back pain and related disability are exorbitantly expensive problems that are difficult to 
solve; they haven’t received adequate attention from policy makers 
Governments can play a key role in resolving some aspects of low back pain related 
problems by altering policies that incentivise work absence, inactivity and work 
disability, and that support ineffective care 
Ineffective, low-value care should be eliminated 
Increased investment in implementation research could uncover why evidence is not 
being taken up in practice and identify and test strategies to ensure rapid uptake of 
evidence into clinical care 
Investment in promoting a healthy lifestyle will reduce low back pain disability and costs 
Research that leads to improved management and prevention of low back pain across 
low-, middle- and high-income countries is an urgent priority 
To identify optimal approaches for the majority of the world’s population, there is a 
need to test suitably considered strategies for the local context in low- and middleincome 
societies 
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Panel 4: Major evidence gaps about low back pain and how to address them 
Evidence gap Addressing the gap 
Population burden 
Low back pain in older age 
groups 
Low back pain in low- and 
middle-income countries 
Population surveys and registries 
Combine datasets for new knowledge without additional cost 
Develop informed perspective on low back pain impact in low and middle income 
countries 
Population monitoring 
Lack of standard low back pain 
definition 
Lack of universal patientrelevant 
outcome measures in 
Agree on and apply a standard definition and new ‘back health’ measure for 
inclusion in national surveys and health care databases that can be compared 
across countries. 
Develop indicators and population surveillance to monitor impact of population 
strategies 
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routine health care 
Health care use (e.g. opioids, 
imaging) 
Occupational data 
Identification of effective and cost-effective treatments for low back pain 
Mechanisms and phenotypes 
of persistent disabling low back 
pain to drive new interventions 
Paucity of highly effective and 
cost-effective interventions for 
low back pain 
Lack of trials of complex 
interventions and including 
complex and older patients 
Commission research on these topics 
o Pathophysiology and prognosis of different low back pain phenotypes 
including trajectories of low back pain from childhood through the life 
course 
o Mechanisms of persistent low back pain 
o Development of theories to guide research integrating pain mechanisms, 
patient perceptions and behaviours, and social determinants of persistent 
low back pain 
Realignment of the research agenda to restrict and focus research funding to 
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Need for new technologies to 
deliver interventions and to 
collect patient data 
important questions that will change practice and/or improve patient-relevant 
outcomes 
Align and combine research questions, priorities and funding, with other health 
conditions to avoid duplication, increase efficiency, and improve the low back pain 
share of research funding; fund more innovations that exist entirely outside of 
health care 
Investigate innovative approaches that combine primary care with occupational 
rehabilitation and multidisciplinary interventions, such as placing musculoskeletal 
therapists as the gatekeepers for all care of low back pain patients and providing 
systems-level support to ensure safe and successful implementation 
Improve the evidence base for individualised and stratified care for people with low 
back pain 
Develop or improve the evidence base for effective prevention of low back pain 
Develop the evidence base for effective management of low back pain in older 
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adults and children 
Implementation of evidence into practice 
Paucity of knowledge about 
how best to improve the 
uptake of low back pain 
evidence into practice 
Realignment of the research agenda to restrict and focus research funding to 
investigate better strategies for implementing what is already known into practice 
Fund evidence syntheses and policy research 
Develop or improve the evidence base for effective prevention of low back pain, 
dysfunction of prolonged disability due to low back pain, and seeking of ineffective 
care 
Develop the evidence base for effective management of low back pain outside of 
health care 
Identification of effective and cost-effective population-based strategies to reduce low back 
pain burden 
Gap in research on how to shift Develop and test strategies designed to address popular misconceptions 
about low 
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cultural beliefs about common 
low back pain 
Lack of integrated research 
programme into prevention of 
long-term disabling conditions 
Lack of trials investigating 
population-level social and 
psychological interventions to 
prevent disability 
How to avoid mistakes of highincome 
countries in low- and 
middle-income countries 
back pain 
Realign the research agenda to focus research funding on important questions that 
will tackle the rising prevalence and burden of disabling low back pain 
Develop or improve the evidence base for low back pain population-based social 
strategies to reduce disability 
Develop or improve the evidence base for promotion of wellbeing despite chronic 
low back pain 
Determine an agenda for research as a priority in low and middle income countries 
Foster links between low-, middle- and high-income countries among policy-makers 
and researchers to allow all countries to benefit from the successes and failures of 
attempts to tackle the burden of low back pain in different settings 
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Panel 5: Indicators that could be used globally for surveillance and monitoring to 
determine whether or not this call to action is yielding positive results 
Number of people with disabling low back pain and their characteristics 
Number of people unable to do activities of daily living because of low back pain 
Number of people not working (whether paid or unpaid) because of chronic low back 
pain 
Number of people unable to participate in usual sport and leisure activities because of 
chronic low back pain 
Number and characteristics of people with low back pain who don’t have any of the 
above problems 
Health care utilization among people with chronic low back pain 
o Number of people undergoing imaging for acute and persisting low back pain 
and the imaging that they receive 
o Number of people with chronic low back pain prescribed/taking opioid 
medication and the duration of use 
o Number of people undergoing spinal injections, the indications for these 
injections, and the injections that they receive 
o Number of people undergoing spinal surgery and other invasive interventions, 
the indications for these interventions, and the specific interventions that they 
receive 
Regular national surveys to determine whether there is a change in population 
knowledge and behaviour over time 
